$2.17
9.96% yesterday
Nasdaq, Apr 28, 10:00 pm CET
ISIN
US7574681034
Symbol
RDHL
Sector
Industry

RedHill Biopharma Ltd. Sponsored ADR Stock price

$2.17
-0.62 22.22% 1M
-6.04 73.57% 6M
-4.04 65.06% YTD
-8.66 79.95% 1Y
-1,797.83 99.88% 3Y
-7,657.83 99.97% 5Y
-14,627.83 99.99% 10Y
Nasdaq, Closing price Mon, Apr 28 2025
-0.24 9.96%
ISIN
US7574681034
Symbol
RDHL
Sector
Industry

Key metrics

Market capitalization $2.77m
Enterprise Value $-11.10m
EV/FCF (TTM) EV/FCF 0.43
EV/Sales (TTM) EV/Sales -0.31
P/S ratio (TTM) P/S ratio 0.08
Short interest 1.75%

Is RedHill Biopharma Ltd. Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

RedHill Biopharma Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast RedHill Biopharma Ltd. Sponsored ADR:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast RedHill Biopharma Ltd. Sponsored ADR:

Buy
100%

Financial data from RedHill Biopharma Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Annually
Dec '23
+/-
%
6.51 6.51
89% 89%
100%
- Direct Costs 3.45 3.45
90% 90%
53%
3.06 3.06
89% 89%
47%
- Selling and Administrative Expenses 29 29
48% 48%
444%
- Research and Development Expense 3.52 3.52
51% 51%
54%
-29 -29
15% 15%
-451%
- Depreciation and Amortization 1.98 1.98
76% 76%
30%
EBIT (Operating Income) EBIT -31 -31
27% 27%
-482%
Net Profit 24 24
133% 133%
366%

In millions USD.

Don't miss a Thing! We will send you all news about RedHill Biopharma Ltd. Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

RedHill Biopharma Ltd. Sponsored ADR Stock News

Neutral
PRNewsWire
about 23 hours ago
Strong Use of Composition-of-Matter Coverage: Patent protects the molecular structure of RHB-107, providing market exclusivity beyond method-of-use claims COVID-19 Therapeutic Use: Includes coverage for treatment of SARS-CoV-2, including wild-type and emerging variants This patent grant enhances RedHill's strategic positioning in the global COVID-19 therapeutic space, a market still expected to...
Neutral
PRNewsWire
12 days ago
The Notification Letter has no immediate effect on the Company's listing on the Nasdaq Capital Market at this time, nor are the Company's business operations affected by receipt of the Notification Letter TEL AVIV, Israel and RALEIGH, N.C. , April 17, 2025 /PRNewswire/ --  RedHill Biopharma Ltd.
Neutral
PRNewsWire
13 days ago
GLP-1 comparable efficacy: Opaganib's positive results, newly published in the journal Diabetes, Metabolic Syndrome and Obesity, demonstrated weight loss and improved metabolic markers on par with semaglutide in preclinical models -- Novel mechanism of action, formulation and administration: Opaganib is a differentiated oral, non-peptide therapeutic that targets sphingosine kinase-2 (SPHK2), po...
More RedHill Biopharma Ltd. Sponsored ADR News

Company Profile

RedHill Biopharma Ltd. is a biopharmaceutical company focusing on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases. It operates through the Commercial Operations segment and the Research & Development segment. The Commercial Operations segment covers all areas relating to the commercial sales and operating expenses directly related to that activity and is being performed by the Company's subsidiary in the United States. The Research & Development segment includes all activities related to the research and development of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Head office Israel
CEO Dror Ben-Asher
Founded 2009
Website www.redhillbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today